Sanofi registers Phase 3 trial of venglustat vs Cerezyme in pediatric Gaucher disease type 3
The study, titled LEAP2KIDS, plans to enroll 18 pediatric participants aged 2 to 11 years with Gaucher Disease Type III who have reached therapeutic goals with enzyme replacement therapy. It is a randomized, open-label, active-comparator trial with a 52-week primary analysis period and a 52-week extended treatment period.
Primary source
ClinicalTrials.gov registry record, November 10, 2026
The Efficacy and Safety of Venglustat Compared With Cerezyme in Pediatric Participants 2 to 11 Years of Age With Gaucher Disease Type 3 (GD3)
Read the source: The Efficacy and Safety of Venglustat Compared With Cerezyme in Pediatric Participants 2 to 11 Years of Age With Gaucher Disease Type 3 (GD3) clinicaltrials.gov
Machine-summarized from the source above; not independently reported. How we use automation